NCT05186922View on ClinicalTrials.gov

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
BIOLOGICAL

CM326

CM326 injection

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05186922 - The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter